Navigation Links
Savient Pharmaceuticals Announces Acceptance of Two Gout-Related,Abstracts for Poster Presentation at the European League Against,Rheumatism (EULAR) 2007 Annual Congress

n. Duke developed the recombinant porcine uricase enzyme and MVP developed the PEGylation technology. MVP and Duke were granted U.S. and foreign patents covering the licensed technology. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

ABOUT SAVIENT PHARMACEUTICALS

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader markets. The Company's lead product development candidate, Puricase(R) for treatment failure gout, has reported positive Phase 1 and 2 clinical data; patient dosing in Phase 3 clinical studies began in May 2006 with patient enrollment completed in March 2007. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Further information on Savient can be accessed by visiting: http://www.savientpharma.com.

FORWARD-LOOKING LANGUAGE

This news release contains forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond Savient's control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections abo
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:12/17/2009)... Dec. 17 Reportlinker.com announces ... is available in its catalogue: ,, ... Pipeline Technology and Market Forecasts to ... ,, Negative Pressure Wound Therapy ... to 2016 ,, Summary ...
(Date:12/17/2009)... -- MedX Limited, the manufacturer and global distributor ... a subsidiary of WellTek Incorporated (OTC Bulletin Board: ... MedX exercise and medical machines ... Germany, India, Scotland, South Korea, Spain and Switzerland. ... will be used in various medical rehabilitation and ...
(Date:12/17/2009)... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today ... at four weeks for the first dose cohort, 200 mg ... combination with pegylated interferon and ribavirin (SOC) in HCV patients. ... levels of virus (<15 IU/ml) at week 4, known as ... RVR, compared to 20% of patients receiving placebo plus SOC. ...
Breaking Medicine Technology:Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 2Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 3Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 4Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 5Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 6WellTek Subsidiary MedX Limited Increases Presence in Global Market 2WellTek Subsidiary MedX Limited Increases Presence in Global Market 3WellTek Subsidiary MedX Limited Increases Presence in Global Market 4ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 2ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 3ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 4ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 5ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 6ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 7Promoting healthy skepticism in the news 3A Helping journalists get it right 61857 1Promoting healthy skepticism in the news 3A Helping journalists get it right 61857 2Effect of real time CPR feedback reported at resuscitation science symposium 61854 1Effect of real time CPR feedback reported at resuscitation science symposium 61854 2Effect of real time CPR feedback reported at resuscitation science symposium 61854 3Saving the single cysteine 3A New antioxidant system found 10846 1Saving the single cysteine 3A New antioxidant system found 10846 2
(Date:12/17/2009)... a recent Thomson Reuters study show that Chinese research ... 1998 to nearly 112,000 in 2008. , Faculty ... the biomedical literature, has evaluated more than 530 papers ... 27 Chinese-authored papers were selected in 2004, this increased ... be even higher in 2009. , Jane Hunter, Managing ...
(Date:12/17/2009)... Inc. (Rutherfordton, N.C.), a management client since 1983, and ... were recently recognized as top-ranked Community Value Providers by ... ... Brentwood, Tenn. (PRWEB) December 17, 2009 -- ... N.C.), a management client since 1983, and Sturgis Hospital ...
(Date:12/17/2009)... Scientific Studies Important ,for the R&D Informatics Industry, , ... ... -- Cambridge Healthtech Institute is pleased to announce the participation ... Adopting R&D Informatics Systems conference to be held on February ... Francisco, CA. This meeting has been integrated in the Informatics ...
(Date:12/17/2009)... SILVER SPRING, Md., Dec. 17 Motionsoft, ... level 1 Payment Card Industry (PCI) Data Security ... a handful of software vendors in the health ... compliance. ,, The PCI Standard is the result ... major credit card companies (Visa International, MasterCard Worldwide, ...
(Date:12/17/2009)... CENTENNIAL, Colo., Dec. 17 AlloSource, one of ... soft tissue allografts for use in surgical procedures and ... substitutes, today announced that is has been selected as ... Alliance (CEBA) Awards, in the Samaritan Institute category honoring ... that AlloSource has been selected as a finalist by ...
Breaking Medicine News(10 mins):Health News:China rapidly catching up in research impact 2Health News:QHR Client Hospitals in North Carolina, Michigan Lauded for Providing Community Value 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 3Health News:Motionsoft Completes PCI Compliance Certification 2Health News:AlloSource Recognized for Exemplifying Ethics Amongst Colorado Non-Profits 2Health News:AlloSource Recognized for Exemplifying Ethics Amongst Colorado Non-Profits 3
... boosts protection for nonsmokers, study finds , , MONDAY, Feb. ... the risk for stroke among women, with more consumption ... , The finding stems from the tracking of both ... of American women across nearly a quarter century. And ...
... Customers and AssociatesLOS ANGELES, Feb. 16 Beginning today, ... screenings including cholesterol, blood pressure, diabetes and body mass ... the most prominent illnesses affecting our country today," says ... these free screenings, we hope to create awareness and ...
... Fewer caloriesFORT WORTH, Texas, Feb. 16 ... industry by becoming the first Mexican brand ... Calorie products. Building on Marinela,s commitment to ... line offers the perfect portions while maintaining ...
... is a statement by American Heart Association President Timothy ... package:Key provisions in the economic stimulus package are a ... challenges with increased financial burdens. Americans suffering from ... crisis -- see a doctor or pay for food ...
... 16 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ) ... manufacture, research, development, marketing and,distribution of probiotics products, today ... 2009 fiscal year, ended December 31, 2008. , , ... -- Net sales increased 32.5% year-over-year to $15.8 ...
... screening, they say , , MONDAY, Feb. 16 ... screening and diagnostic for breast cancer, not serve as ... guidelines. , The guidelines, published Monday in the ... give needed direction for using breast MRI, a relatively ...
Other Medicine News:Health News:Coffee Drinking Lowers Women's Stroke Risk 2Health News:Coffee Drinking Lowers Women's Stroke Risk 3Health News:Coffee Drinking Lowers Women's Stroke Risk 4Health News:Marinela USA(R) Launches 100 Calorie Product Line 2Health News:Statement by American Heart Association President Timothy Gardner, M.D. on Congressional Approval of Economic Stimulus Package 2Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 2Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 3Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 4Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 5Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 6Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 7Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 8Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 9Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 10Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 11Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 12Health News:Experts Release Guidelines on Use of Breast MRI 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: